Hiding in Plain Sight: Cell Biomimicry for Improving Hematological Cancer Outcomes

TL;DR

This paper explores how mimicking cell structures can improve drug delivery for blood cancers by avoiding immune detection and increasing treatment effectiveness.

Contribution

The paper highlights the novel use of biomimicry in nanoparticle design to evade immune clearance and enhance cancer targeting.

Findings

Biomimetic nanoparticles can avoid immune clearance and prolong circulation time.

This approach leads to homotypic targeting and reduced cancer cell vitality.

In vivo and in vitro studies support improved survival outcomes in hematologic cancers.

Abstract

The field of nanomedicine has been fruitful in creating novel drug delivery ideas to battle hematologic cancers. However, one persistent barrier to efficient nanoparticle treatment is phagocytic uptake or the clearance of nanoparticles by immune cells. To prevent this immune uptake, scientists have utilized biomimicry, the emulation of natural structures for engineered applications, to create particles that are able to remain unrecognized by immune cells. This method aims to improve the overall circulation time of nanoparticles by decreasing the amount of particles filtered out of the blood. It can even lead to homotypic cancer cell targeting, decreasing cancer cell vitality. This review summarizes recent in vivo and in vitro studies to prove that biomimetic cargo delivery is a unique and tenable way of increasing survival outcomes in patients with hematologic cancers.

Figures